

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <a href="https://www.bccancer.bc.ca/terms-of-use">www.bccancer.bc.ca/terms-of-use</a> and according to acceptable standards of care.

PROTOCOL CODE: BRAJTR

Page 1 of 2

| DOCTOR'S                                                                                                                                                                         | ORDERS               | Ht                      | cm           | Wt              | kg              | BSA              | _m²        |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-------------------------|--------------|-----------------|-----------------|------------------|------------|
| REMINDER: Plea                                                                                                                                                                   | ase ensure drug al   | lergies and previou     | ıs bleomyci  | n are           | documented      | on the Allergy & | Alert Form |
| DATE:                                                                                                                                                                            |                      | To be given:            |              |                 | Cycle # of      | Trastuzumab:     |            |
| Date of Previous Cycle:                                                                                                                                                          |                      |                         |              |                 |                 |                  |            |
| Indicate the number of trastuzumab doses patient has received together with chemotherapy (not as single agent) to date:                                                          |                      |                         |              |                 |                 |                  |            |
| **Have Hypersensitivity Reaction Tray and Protocol Available**                                                                                                                   |                      |                         |              |                 |                 |                  |            |
| TREATMENT:                                                                                                                                                                       | TREATMENT:           |                         |              |                 |                 |                  |            |
| <ul> <li>☐ Cycle 1 Only (NEW patients ONLY – Omit for patients continuing single-agent trastuzumab following a trastuzumab-containing chemotherapy regimen)</li> </ul>           |                      |                         |              |                 |                 |                  |            |
| <b>trastuzumab 8 mg/kg</b> x kg = mg IV in NS 250 mL over 1 hour 30 minutes. Observe for 1 hour post-infusion.                                                                   |                      |                         |              |                 |                 |                  |            |
| Pharmacy to sele                                                                                                                                                                 |                      | as per Provincial Syste |              |                 |                 |                  | _          |
| Drug                                                                                                                                                                             | Brand (Pharmacis     | t to complete. Please   | print.)      | Ph              | armacist Initia | I and Date       | 4          |
| trastuzumab                                                                                                                                                                      |                      |                         |              |                 |                 |                  |            |
| OR                                                                                                                                                                               | •                    |                         |              |                 |                 |                  | _          |
| ☐ Cycle 2                                                                                                                                                                        |                      |                         |              |                 |                 |                  |            |
| trastuzumab 6 mg/kg x kg =mg IV in NS 250 mL over 1 hour. Observe for 30 minutes post-infusion.                                                                                  |                      |                         |              |                 |                 |                  |            |
| Pharmacy to sele                                                                                                                                                                 | ct trastuzumab brand | as per Provincial Syste | emic Therapy | Policy          | III-190         |                  |            |
| Drug                                                                                                                                                                             | Brand (Pharmacis     | t to complete. Please   | print.)      | Ph              | armacist Initia | I and Date       | ]          |
| trastuzumab                                                                                                                                                                      |                      |                         |              |                 |                 |                  |            |
| <u> </u>                                                                                                                                                                         |                      |                         |              |                 |                 |                  |            |
|                                                                                                                                                                                  |                      |                         |              |                 |                 |                  |            |
| ☐ Cycle 3 and subsequent (maximum 17 cycles total including previous adjuvant chemotherapy containing                                                                            |                      |                         |              |                 |                 |                  |            |
| trastuzumab:  trastuzumab 6 mg/kg x kg = mg IV in NS 250 mL over 30 minutes x cycle(s). Observe for 30 minutes post-infusion (not required after 3 treatments with no reaction). |                      |                         |              |                 |                 |                  |            |
| Pharmacy to select trastuzumab brand as per Provincial Systemic Therapy Policy III-190                                                                                           |                      |                         |              |                 |                 |                  |            |
| Drug                                                                                                                                                                             |                      |                         |              | armacist Initia | nitial and Date |                  |            |
| trastuzumab                                                                                                                                                                      |                      |                         |              |                 |                 |                  |            |
|                                                                                                                                                                                  | <u> </u>             |                         |              |                 |                 |                  | _          |
| acetaminophen 325 to 650 mg PO PRN for headache and rigors                                                                                                                       |                      |                         |              |                 |                 |                  |            |
|                                                                                                                                                                                  |                      |                         |              |                 |                 |                  |            |
| Proceed with treatment based on blood work from                                                                                                                                  |                      |                         |              |                 |                 |                  |            |
| DOCTOR'S SIGNATURE:                                                                                                                                                              |                      |                         |              |                 |                 | UC<br>SIGNATURE: |            |



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <a href="https://www.bccancer.bc.ca/terms-of-use">www.bccancer.bc.ca/terms-of-use</a> and according to acceptable standards of care.

PROTOCOL CODE: BRAJTR

Page 2 of 2

| RETURN APPOINTMENT ORDERS                                                                                                                 |                  |  |  |  |  |  |
|-------------------------------------------------------------------------------------------------------------------------------------------|------------------|--|--|--|--|--|
| <ul> <li>☐ Return in three weeks for Doctor and Cycle</li> <li>☐ Return in weeks for Doctor and Last Cycle. Return in weeks</li> </ul>    |                  |  |  |  |  |  |
| <b>MUGA Scan or Echocardiogram</b> every ☐ 3 months or ☐ 4 months from onset of trastuzumab and upon completion of treatment (17 cycles). |                  |  |  |  |  |  |
| If clinically indicated xweeks:                                                                                                           |                  |  |  |  |  |  |
| ☐ CBC & Diff, platelets prior to next treatment                                                                                           |                  |  |  |  |  |  |
| ☐ ECG ☐ Echocardiogram ☐                                                                                                                  | ☐ MUGA Scan      |  |  |  |  |  |
| ☐ CA15-3 ☐ Bilirubin ☐                                                                                                                    | ☐ <b>GGT</b>     |  |  |  |  |  |
| ☐ Alk Phos ☐ ALT ☐                                                                                                                        | LDH Creatinine   |  |  |  |  |  |
| ☐ Other tests:                                                                                                                            |                  |  |  |  |  |  |
| ☐ Consults:                                                                                                                               |                  |  |  |  |  |  |
| ☐ See general orders sheet for additional                                                                                                 |                  |  |  |  |  |  |
| DOCTOR'S SIGNATURE:                                                                                                                       | UC<br>SIGNATURE: |  |  |  |  |  |